Previous Projects
Longstanding Relationship in Vaccine Research
Vaccine research is a key pillar of the IDCTU's mission. Historically, the projects we focused on involved viruses that threaten the surrounding community in hopes to limit the severity of influenza, Respiratory Syncytial Virus (RSV), Clostridium Difficile C. Diff severity of Extraintestinal Pathogenic Escherichia coli (ExPEC) infections. Furthermore, we were involved in some of the earlier safety and efficacy testing of the COVID-19 vaccine.
- Influenza
-
- A Phase 3, Randomized Observer-Blinded Study to Evaluate the Efficacy, Safety, Tolerability, and Immunogenicity of a Modifiefd RNA Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age or Older (NCT05540522 | Publication)
- A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza in Healthy Individuals (NCT05052697 | Publication)
- COVID-19
-
- Comparative immunogenicity of concomitant vs sequential bivalent mRNA and influenza vaccination (NCT06020118)
- A Phase 3 Master Protocol to Evaluate Additional Dose(S) of Bnt162b2 In Healthy Individuals Previously Vaccinated with Bnt162b2 (NCT04955626 | Publication)
- A Phase 1/2/3, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of Sars-Cov-2 Rna Vaccine Candidates Against Covid-19 in Healthy Individuals (NCT04368728 | Publication)
- of Coronavirus Disease 2019 in First Responder - The project aims to determine the frequency of exposure to COVD-19 disease, caused by the novel coronavirus among first responders by testing a broad range of police officers, fire fighter, emergency medical technician and paramedic for the antibody in the blood, which indicates a past infection. (Publication)
- Respiratory Syncytial Virus (RSV)
-
- A Phase 3 Master Protocol to Evaluate The Safety, Tolerability, and Immunogenicity of Respiratory Syncytial Virus (Rsv) Prefusion F Subunit Vaccine in Adults at High Risk of Severe RSV Disease (NCT05842967 | Publication)
- Clostridioides Difficile (C.diff)
-
- A Phase 3, Placebo-Controlled, Randomized, Observer-Blinded Study to Evaluate the Efficacy, Safety, and Tolerability of a Clostridium Difficile Vaccine in Adults 50 Years of Age and Older (NCIT03090191 | Publication)
- Extraintestinal Pathogeic Escherichia coli (ExPEC)
-
Extraintestinal Pathogenic Escherichia coli (ExPEC) can cause everything from urinary tract infections (UTIs), bacteremia, to neonatal meningitis.
- Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Assess the Efficacy, Safety and Immunogenicity of Vaccination with Expec9v in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years and Older with a History of Urinary Tract Infection in the Past 2 Years (NCT04899336)
Antimicrobial Research
Another priority for the IDCTU is being on the forefront for developing effective modern treatment plans. We have previously been involved in research which focused on optimizing treatment to maximize the impact of existing antimicrobial agents.
- A Multicenter, Double-Blind, Randomized, Comparative Study of the Safety, Tolerability, Efficacy, and Pharmacokinetics of CF-301 vs. Placebo in Addition to Standard-of-Care Antibacterial Therapy for the Treatment of Adult Patients with Staphylococcus aureus Bloodstream Infections (Bacteremia) Including Endocarditis (NCT03163446 | Publication)
- MDRO: Study of Highly Resistant Escherichia coli (SHREC) Antibiotic Resistance Leadership Group (ALRG) (NCT04574596)